Equities
Health CareMedical Equipment and Services
  • Price (EUR)25.70
  • Today's Change-0.25 / -0.96%
  • Shares traded1.13m
  • 1 Year change-3.53%
  • Beta0.5840
Data delayed at least 15 minutes, as of Oct 31 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amplifon SpA is an Italy-based company active in the hearing care retail market. The Company provides personalized solutions and customer care to hearing-impaired people. It offers a wide range of services from diagnosing hearing difficulties, to fitting, servicing and maintaining hearing aids. The Company is organized in three geographical operating segments: Europe, Middle East and Africa - EMEA - (Italy, France, The Netherlands, Germany, the United Kingdom, Ireland, Spain, Portugal, Switzerland, Belgium, Luxemburg, Hungary, Egypt, Turkey, Poland and Israel), Americas (USA, Canada, Chile, Argentina, Ecuador, Colombia, Panama and Mexico) and Asia-Pacific (Australia, New Zealand, India and China).

  • Revenue in EUR (TTM)2.32bn
  • Net income in EUR161.58m
  • Incorporated--
  • Employees14.38k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AMP:MIL since
announced
Transaction
value
Miracle-Ear Centers of Arkansas LLCDeal completed22 Jan 202422 Jan 2024Deal completed-12.35%--
Las Davis Enterprises IncDeal completed22 Jan 202422 Jan 2024Deal completed-12.35%--
Hearing Pro IncDeal completed22 Jan 202422 Jan 2024Deal completed-12.35%--
Audical SRLAnnounced13 Dec 202313 Dec 2023Announced-12.73%--
Living Sounds Hearing CentreDeal completed30 Nov 202330 Nov 2023Deal completed-8.99%--
Data delayed at least 15 minutes, as of Oct 31 2024 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ambu A/S705.54m60.33m4.05bn4.82k75.945.9536.585.731.691.6919.8021.600.74592.187.171,140,165.006.383.817.374.6258.8859.378.555.431.5174.380.096122.897.4512.8880.65-13.006.67--
Getinge AB2.90bn145.90m4.24bn11.85k31.161.7413.371.466.216.21123.33111.090.59372.517.302,861,487.003.015.314.006.9845.8047.835.078.690.596510.340.262937.8712.495.66-3.17---0.394434.49
Sectra AB156.18m38.59m4.48bn1.22k123.9533.5094.8628.662.312.319.368.550.6136--3.631,503,436.0015.1615.7528.0829.5247.0164.9524.7119.59----0.0270.0026.844.0614.2516.5848.37--
SCHOTT Pharma AG & Co KgaA948.56m150.41m4.54bn4.65k30.085.9121.434.781.001.006.315.100.74344.344.07204,166.2011.82--16.42--34.18--15.90--1.06--0.1086--9.43--21.11------
ConvaTec Group PLC2.03bn141.13m5.36bn10.13k38.073.5115.652.640.05750.05750.82580.62290.59652.475.89167,589.004.152.364.742.7355.9655.036.964.341.272.960.4604127.293.373.18107.15-6.9312.3731.41
Carl Zeiss Meditec AG2.07bn203.20m5.42bn4.95k26.58----2.622.282.2823.14--------428,397.90--9.56--11.7255.1257.849.8413.15------34.479.8010.28-1.2018.0926.7914.87
Ypsomed Holding AG582.88m83.28m5.61bn2.30k67.328.5434.419.625.745.7440.1845.260.55875.404.96238,875.007.984.4112.406.8134.4727.2614.297.380.596720.890.29320.5010.253.8652.835.448.6429.46
DiaSorin SpA1.16bn167.74m5.67bn3.19k33.663.3518.684.893.013.0121.7830.310.36681.266.09359,117.205.2810.305.7811.5064.8166.7014.4021.251.8912.280.389224.71-15.6411.40-33.650.216716.49--
Amplifon SpA2.32bn161.58m5.87bn14.38k36.285.1613.232.530.71530.715310.275.030.622921.4610.96161,594.304.334.316.535.8124.5659.016.957.280.39926.120.592134.266.6510.66-12.219.0812.6815.68
Demant A/S3.00bn354.98m7.63bn21.50k21.485.94--2.5411.9810.92101.2343.360.71922.035.681,034,778.008.528.2711.6813.2375.4574.1411.8511.341.065.580.62440.0013.8910.0012.236.968.80--
Data as of Oct 31 2024. Currency figures normalised to Amplifon SpA's reporting currency: Euro EUR

Institutional shareholders

12.00%Per cent of shares held by top holders
HolderShares% Held
Comgest SAas of 28 Jun 20245.23m2.31%
The Vanguard Group, Inc.as of 02 Oct 20244.46m1.97%
Allianz Global Investors GmbHas of 30 Aug 20242.85m1.26%
Cr�dit Mutuel Asset Management SAas of 28 Mar 20242.42m1.07%
T. Rowe Price International Ltd.as of 30 Sep 20242.37m1.05%
BlackRock Fund Advisorsas of 03 Oct 20242.35m1.04%
Amundi Asset Management SA (Investment Management)as of 02 Oct 20242.19m0.97%
Norges Bank Investment Managementas of 02 May 20242.06m0.91%
DNCA Finance SAas of 31 Dec 20231.67m0.74%
Mirova SA (Investment Management)as of 31 May 20241.57m0.70%
More ▼
Data from 30 Jun 2024 - 23 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.